期刊文献+

有机阳离子转运体2、微小RNA-21的表达水平与前列腺癌患者临床病理特征及预后的相关性 被引量:1

Correlations of expression levels of organic cation transporter 2 and microRNA-21 with clinicopathological features and prognosis in patients with prostate cancer
在线阅读 下载PDF
导出
摘要 目的探讨有机阳离子转运体2(OCT2)、微小RNA-21(miR-21)的表达水平与前列腺癌患者临床病理特征及预后的相关性。方法选取105例前列腺癌患者作为观察组,89例良性前列腺增生患者作为对照组。通过免疫组化法检测两组患者病灶组织中OCT2及miR-21的表达情况,并分析OCT2及miR-21的表达情况与前列腺癌患者临床病理特征及预后的关系。结果免疫组化结果显示,OCT2主要分布于细胞质中,miR-21主要分布于细胞膜中,阳性细胞呈棕黄色;观察组患者的OCT2高表达率低于对照组,而miR-21高表达率高于对照组(均P<0.05)。临床分期为T 1~T 2期、无淋巴结转移、无远处转移、前列腺特异性抗原(PSA)水平在5~15 ng/mL之间、Gleason评分<7分、低中危前列腺癌患者的OCT2高表达率更高,miR-21高表达率更低(均P<0.05);而不同年龄、吸烟情况的前列腺癌患者病灶组织中的OCT2及miR-21高表达率比较,差异均无统计学意义(均P>0.05)。Kaplan-Meier生存分析结果显示,OCT2高表达患者的总生存率(93.3%)高于低表达率患者(75.4%),而miR-21高表达患者的总生存率(73.2%)低于低表达患者(95.0%)(均P<0.05)。多因素Cox回归分析结果显示,前列腺癌组织中的OCT2和miR-21表达情况、临床分期、淋巴结转移情况、远处转移情况、PSA水平、Gleason评分、危险分级均为前列腺癌患者预后的独立影响因素(均P<0.05)。结论在前列腺癌组织中OCT2呈低表达,而miR-21呈高表达,其与前列腺癌患者的临床分期、淋巴结转移情况、远处转移情况、PSA水平、Gleason评分和危险分级相关,且均为前列腺患者预后的独立影响因子。 Objective To investigate the correlations of the expression levels of organic cation transporter 2(OCT2)and microRNA-21(miR-21)with the clinicopathological features and prognosis in patients with prostate cancer.Methods A total of 105 patients with prostate cancer were selected as observation group,and 89 patients with benign prostatic hyperplasia as control group.The expression of OCT2 and miR-21 in the lesions of patients in the two groups was detected by immunohistochemistry assay,and the relationships of the expression of OCT2 and miR-21 with the clinicopathological features and prognosis in patients with prostate cancer were analyzed.Results Immunohistochemical results showed that OCT2 was mainly distributed in the cytoplasm,miR-21 was mainly distributed in the cell membrane,and the positive cells presented tan.The observation group exhibited a lower rate of high expression of OCT2 and a higher rate of high expression of miR-21 than the control group(all P<0.05).Prostate cancer patients with clinical stage T 1 to T 2,no lymph node metastasis,no distant metastasis,prostate-specific antigen(PSA)level ranged from 5 to 15 ng/mL,Gleason score<7,or low and moderate risk of prostate cancer had a higher rate of high expression of OCT2 and a lower rate of high expression of miR-21(all P<0.05);there was no statistically significant difference in the rate of high expression of OCT2 or miR-21 in the lesions between prostate cancer patients in different age groups or with different smoking conditions(all P>0.05).The results of Kaplan-Meier survival analysis showed that the overall survival rate of patients with high expression of OCT2(93.3%)was higher than that of patients with low expression(75.4%),while the overall survival rate of patients with high expression of miR-21(73.2%)was lower than that of patients with low expression(95.0%)(all P<0.05).The results of multivariate Cox regression analysis revealed that the expression of OCT2 and miR-21 in prostate cancer tissues,clinical stage,lymph node metastasis,distant metastasis,PSA level,Gleason score,and risk grade were independent influencing factors for the prognosis of patients with prostate cancer(all P<0.05).Conclusion OCT2 is lowly expressed and miR-21 is highly expressed in prostate cancer tissues,which is related to the clinical stage,lymph node metastasis,distant metastasis,PSA level,Gleason score,and risk grade of patients with prostate cancer,and all are independent influencing factors for the prognosis of patients with prostate cancer.
作者 穆元忠 郭虎林 杨世荣 赵刚 MU Yuan-zhong;GUO Hu-lin;YANG Shi-rong;ZHAO Gang(Department of Urology,the Fifth People′s Hospital of Qinghai Province,Xining 810007,China)
出处 《广西医学》 CAS 2022年第8期857-862,共6页 Guangxi Medical Journal
关键词 前列腺癌 有机阳离子转运体2 微小RNA-21 病理特征 预后 Prostate cancer Organic cation transporter 2 MicroRNA-21 Pathological feature Prognosis
作者简介 穆元忠(1982-),男,本科,副主任医师,研究方向:泌尿外科,电子邮箱:554727303@qq.com。
  • 相关文献

参考文献12

二级参考文献143

  • 1冯旺琴,崔竹梅,刘芝华,李玉军.S100A8和S100A9在子宫颈鳞癌组织中的表达[J].现代肿瘤医学,2008,16(11):1969-1972. 被引量:7
  • 2Stefano Arcangeli,Valentina Pinzi,Giorgio Arcangeli.Epidemiology of prostate cancer and treatment remarks[J].World Journal of Radiology,2012,4(6):241-246. 被引量:18
  • 3赵彤,朱梅刚,黄宗义,张亚历,张素娟,李梅芳.肺癌癌基因蛋白产物同步检测的对比分析[J].癌症,1995,14(1):13-15. 被引量:54
  • 4谷化平,冯和平,徐志勇,苏红.免疫组化在恶性黑色素瘤诊断中的作用[J].中国肿瘤临床,1996,23(8):599-600. 被引量:4
  • 5Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality[J]. Int J Cancer, 2000,85 (1) : 60-67.
  • 6Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p[J]. Nat Genet, 2001,27 (2) 172-180.
  • 7Rebbeck TR,Walker AH, Zeigler-Johnson C, et al. Association of HPC2/ELAC2 genotypes and prostate cancer[J].Am J Hum Genet, 2000,67(4) : 1014-1019.
  • 8Severi G, Giles GG, Southey MC, et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer[J].J Natl Cancer Inst, 2003,95 (11) : 818-824.
  • 9Adler D,Kanji N,Trpkov K,et al. HPC2/ELAC2 gene vari- ants associated with incident prostate cancer[J]. J Hum Genet,2003,48(12) :634-638.
  • 10Xu B,Tong N,Li JM,et al. ELAC2 polymorphisms and pros- tate cancer risk: a meta-analysis based on 18 case-control studies[J]. Prostate Cancer Prostatic Dis, 2010, 13 (3):270- 277.

共引文献2248

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部